LAWSUITS NEWS & LEGAL INFORMATION
Search Results for
Sort by relevance 131 pages found matching glaxo- Avandia Remains on Market Despite Health Risks
Aug-7-07 Los Angeles, CA: Despite expert testimony about its side effects risk, a Food and Drug Administration advisory committee has recommended that the diabetes drug Avandia should be allowed to stay on the market. But while the committee did not call for an Avandia recall, it says that the drug's label should carry a stronger warning about its risk of causing... - Avandia Drug Maker's Stock Rises: FDA "Dropped the Ball" says Congressman
Aug-7-07 Gaithersburg, MD The International Herald Tribune reports that shares of GlaxoSmithKline, the maker of Avandia , rose the most in two years last week, after a U.S. FDA panel recommended that Avandia be kept on the market. The FDA panel was organized by U.S. Rep. Henry Waxman (D-California), who stated he believes the FDA may not be adequately requir... - Avandia Debacle Exposes Big Pharma's FDA Mole
Aug-6-07 Washington, DC: In May 2007, FDA spokesperson Douglas Arbesfeld made headlines when he waged a smear campaign against cardiologist Dr Steve Nissen, after his study in the New England Journal of Medicine showed the diabetes drug Avandia, sold by GlaxoSmithKline, allegedly increased the risk of heart attacks by 43% and cardiovascular deaths by possibly 64%... - Is Avandia Safe? Depends On Who You Talk To
Aug-5-07 Gaithersburg, MD When Dr. David Graham testified at the federal drug panel July 30th, reviewing the fate of diabetes drug Avandia and its alleged relationship to heart attack, stroke and kidney failure, he didn't mince words. "It's well established that rosiglitazone increases congestive heart failure," he said. The drug safety reviewer with the U.S... - Avandia Defended by Glaxo Despite Heart Attack Risk
Aug-2-07 Rockville, MD As part of the July 30th proceedings of a federal drug advisory committee that ultimately voted to keep Avandia on the market despite cardiovascular risk, Avandia maker GlaxoSmithKline defended its product as completely safe. Dr. Murray Stewart, A Vice President with the company, presented the findings of an examination of data from more... - Lawsuits Against Glaxo Rise as Avandia Sales Plummet
Aug-1-07 Washington, DC: A study released in July 2007, by the Federal Agency for Health Care Research and Quality, reported that the older diabetes drugs, available for as little as $10 a month, are as safe and effective as the newer drugs like Avandia (rosiglitazone), which costs between $131 and $262 a month. On July 20, 2007, Science Daily reported that li... - Avandia Allowed to Continue, Despite Risks
Jul-31-07 Gaithersburg, MD: Avandia , it seems, is back. In a remarkable turn of events, the diabetes drug that was vilified for cardiovascular risks only a few short months ago and made headlines around the world, was given a new lease on life by a federal drug advisory committee Monday. The vote to allow Avandia to remain on the market was described as 'overwh... - FDA Scientist Graham Calls Glaxo Avandia Trial Useless
Jul-30-07 Washington, DC: World-renowned cardiologist Dr Steven Nissen and statistician Kathy Wolski of the Cleveland Clinic posted a study online on May 21, 2007, to warn the public that the diabetes drug Avandia (rosiglitazone) increased the risk of heart attacks by 43% and the risk of death from cardiovascular causes by possibly 64%. A print edition of the s... - Avandia Warnings might have prevented a Death
Jul-27-07 Dallas, TX Neil Pender's father passed away five years ago from a heart attack and he is angry. "My father started taking Avandia shortly after it was approved in 1999 but we didn't hear about the dangers of this drug until June of this year," says Pender. "My father, Roy, wasn't aware that he was a diabetic, but he did have high blood pressure," say... - CDC Leads SSRI Disinformation Media Blitz
Jul-20-07 Washington, DC: In a June 27, 2007 press release that made headlines all over the world the US Centers for Disease Control announced that birth defects associated with the use of antidepressants by pregnant women are rare. As proof for this claim, the CDC cited two new studies published in the New England Journal of Medicine. Over the following 2 week... - VA Patient Quits Avandia
Jul-18-07 Fall River, MA Steve G. was diagnosed with diabetes in the late 1990s and started a treatment program that involved several medicaitons. His health was under control until October, 2005 when his doctor at the VA hospital prescribed Avandia . About one month later, he started having breathing problems. "Then I had a lot of pressure in my chest so I wou... - Scientists Demand Action on Avandia: New FDA Panels Formed
Jul-8-07 Cleveland, OH: At the recent American Diabetes Association's annual meeting in Chicago, Dr. Steven Nissen, chief of cardiology at the Cleveland Clinic, said early data on links between Avandia and cardiac events were ignored by the drug's maker, Glaxo Smith Klein, including findings presented at the FDA advisory meeting prior to Avandia's approval. "... - Part 2: Avandia, the FDA and the consumer: first lawsuit filed
Jun-25-07 Beaumont, TX: It is now one month since GlaxoSmithKline's popular diabetes drug Avandia was reported to carry with it a higher risk of heart attack—and just two days ago, on June 19, what is likely the first lawsuit blaming Glaxo for contributing to just such a heart attack, was filed. Larry Alan Stanford, 60, of Beaumont, Texas, suffered a hear... - Avandia Canada Heart Attack and Liver Damage.
A new study from the New England Journal of Medicine published May 21, 2007 links the widely prescribed diabetes drug Avandia to an alleged increased risk of heart attack and even death. The Journal reported that dozens of studies together resulted in alleged evidence of a 43 percent higher risk of heart attack. Since Avandia was approved by the FDA i... - Part 1: Avandia and the FDA: The Bottom Line
Jun-19-07 Washington, DC The FDA has come under vocal criticism in the last three weeks over its handling of Avandia , the widely-prescribed GlaxoSmithKline diabetes drug. The FDA's supporters and its critics are still offering their views of what happened, what should have happened, and what should happen in the future. As regular readers will know, Avandia wa... - New diet drugs Alli and Zimulti awaken memories of Fen-Phen and PPH
Jun-18-07 New York, NY This week two new diet drugs jumped into the news media. The first, Orlistat (Alli), is just now on the drugstore shelves, and the second, Rimonabant (Zimulti), is going through the FDA approval process. Will they prove to be PPH diet drugs like Fen-phen? It's been 10 years since Fen-phen was withdrawn from the market because too many peo... - Glaxo now faces Lawsuit by Shareholders over Avandia Problems
Jun-16-07 New York, NY GlaxoSmithKline PLC, the maker of the popular diabetes drug Avandia, just can't stay out of the news. And the news is all bad. Since May 21, when a meta-analysis (that is, an analysis of pooled data) of 42 clinical trials involving nearly 28,000 diabetes patients was published, showing that those taking Avandia had a 43% higher risk of... - Lawmakers Go After Thugs at FDA Over Avandia
Jun-11-07 Washington, DC: In one of the latest developments in the Avandia diabetes drug saga, on June 7, 2007, a bipartisan group of powerful lawmakers sent a letter to FDA asking Commissioner Andrew von Eschenbach for an explanation of the agency's policy on conflicts of interest regarding hiring employees directly from drug companies regulated by the FDA. At... - Avandia Researcher Under Fire
Jun-8-07 Cleveland, OH Over the past few days reports have surfaced about the risk of heart attacks associated with diabetes drug Avandia. Since the findings of a study that showed an increased risk of heart attack in patients taking Avandia were published, reports have surfaced that both the Food and Drug Administration (FDA) and GlaxoSmithKline, the drug's manu... - Fireworks on Capitol Hill: FDA on the Defensive, Avandia Warnings Toughened
Jun-7-07 Washington, DC In an obvious attempt to save face, the U.S. Food and Drug Administration (FDA) yesterday announced severely toughened black box warnings for Avandia , and Actos - two diabetes drugs strongly suspected of increasing the risk of heart attack. In front of a packed Congressional hearing yesterday called to investigate the long delays by reg...